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Fc receptors are important for the clinical efficacy of ther-
apeutic antibodies. Bispecific antibodies (BsAb) are
immunoglobulin-conjugates with two different binding
specifities, targeting tumor antigens and effector cell trig-
ger molecules. BsAb, produced by chemical coupling of
one antibody against a tumor cell surface antigen with
another against a Fc receptor, mediate effective interac-
tions between effector and target cells.
Here, genetically coupled bispecific single chain Fv (bss-
cFv) were produced – as they easily enable further modifi-
cations of the molecule – directed against one of the
effector cell antigens FcαRI (CD89) or FcγRIII (CD16) and
against HLA class II or Lym-2. Lym-2 represents a variant
form of the HLA-DR antigen and is highly expressed on
the surface of malignant B cells, but only at low levels on
normal cells. HLA class II and Lym-2 are both known as
effective targets for effector cell-mediated lysis of malig-
nant human B-lymphoid cells. CD89 is an interesting trig-
ger molecule for BsAb therapy, as it recruits neutrophils as
effector cells, which have tumor cytolytic potential against
a broad spectrum of tumor cells and are the most abun-
dant circulating blood leukocytes. Antibodies against
CD16 have already shown biological activity in vitro and
in tumor patients by recruting NK cells. The two compo-
nent scFv were fused via a flexible 20aa linker. ScFv frag-
ments were generated by producing phage display
libraries from corresponding hybridomas, and screening
the libraries with antigen-positive cells. Recombinant scFv
against HLA class II, Lym-2, CD89 and CD16 were thus
obtained from the hybridomas F3.3, Lym-2, A77 and 3G8
respectively. Functional bsscFv were expressed and
secreted by insect cells and were purified via Nickel
chelate chromatography. Purified BsAb reacted with HLA
class II or Lym-2-positive target cells and one of the effec-
tor cell antigens, CD89 or CD16, respectivly. In ADCC
experiments all constructs mediated specific lysis of HLA
class II or Lym-2-positive malignant human B-lymphoid
cell lines with human MNC or PMN as effector cells. The
[CD89 x HLA class II] and the [CD16 x HLA class II] bss-
cFv also mediated significant lysis of primary cells from
patients with B-cell chronic lymphocytic leukaemia (B-
CLL). In conclusion, these recombinant bsscFv may allow
the specific recruitment of effector cells for an improved
therapy in B-lymphoid malignancies.
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